Skip to main content
Fig. 6 | BMC Genomic Data

Fig. 6

From: Comprehensive analysis of m6A regulators and relationship with tumor microenvironment, immunotherapy strategies in colorectal adenocarcinoma

Fig. 6

The value of m6Ascore in predicting response of patients to therapeutic treatments. A The IPS scores of anti-PD1 and anti-CTLA4 alone and in combination use were higher in high-m6Ascore group which demonstrated that patients in this group had great sensitivity to anti-PD1 and anti-CTLA4 treatments (P < 0.001). B The m6A score was higher in patients with MSI-H group who was know to be more sensitive to immunotherapy. C The pRRophetic algorithm was used to predict the sensitivity of 15 commonly used drugs in high- and low-m6Ascore group patients. The lower IC50 level indicates more sensitive to the drugs

Back to article page

BMC Genomic Data

ISSN: 2730-6844

Contact us